series-a
Stage
2024
Founded
2
Investors
About
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal antibodies targeting TSLP and related pathways to treat serious immunological conditions such as asthma and COPD.
Explore Windward Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.